Clinical Trial Update: ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating immune checkpoint inhibitors with or without anti-VEGF antibody or tyrosine kinase inhibitors for advanced hepatocel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: HCC - Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING